Bristol Myers Squibb is committed to helping appropriate patients get access to our
medications by providing access and reimbursement support services.

This information is intended for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.

Billing and
Diagnosis Codes

Metastatic Non-Small Cell Lung Cancer (mNSCLC) Monotherapy

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Reimbursement and Coding Guide for OPDIVO
Download

Filter by keyword Clear Filter
Type a keyword to find a specific HCPCS, CPT, NDC, or ICD-10 code
Healthcare Common Procedure Coding System (HCPCS) Codes1 Issued by CMS
J9299

COPY

Injection, nivolumab, 1 mg

Providers and suppliers are required to report the JW modifier on Part B drug claims for discarded drugs and biologicals. Also, providers and suppliers must document the amount of discarded drugs or biologicals in Medicare beneficiaries’ medical records.2

Revenue Codes (for Use in the Hospital Outpatient Setting)3
0636

COPY

Drugs requiring detailed coding

0335

COPY

Chemotherapy administration, IV

0260

COPY

IV Therapy-General

Current Procedural Terminology (CPT)4,†
96413

COPY

Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

National Drug Codes (NDC)5 Issued by the FDA

Note:Payers require the submission of the 11-digit NDC on healthcare claim forms. Please use the 11-digit codes shown here.

00003-3772-11

COPY

40 mg/4 mL (10 mg/mL) single-dose vial

00003-3774-12

COPY

100 mg/10 mL (10 mg/mL) single-dose vial

00003-3756-14

COPY

120 mg/12 mL (10 mg/mL) single-dose vial

00003-3734-13

COPY

240 mg/24 mL (10 mg/mL) single-dose vial

International Classification of Diseases, Tenth Revision, Clinical Modification Diagnosis Codes (ICD-10-CM)6
C33

Malignant neoplasm of trachea

C34

Malignant neoplasm of bronchus and lung

C34.0

Malignant neoplasm of main bronchus, carina, and hilus of lung

C34.00

COPY

Malignant neoplasm of unspecified main bronchus

C34.01

COPY

Malignant neoplasm of right main bronchus

C34.02

COPY

Malignant neoplasm of left main bronchus

C34.1

COPY

Malignant neoplasm of upper lobe, bronchus or lung

C34.10

COPY

Malignant neoplasm of upper lobe, unspecified bronchus or lung

C34.11

COPY

Malignant neoplasm of upper lobe, right bronchus or lung

C34.12

COPY

Malignant neoplasm of upper lobe, left bronchus or lung

C34.2

COPY

Malignant neoplasm of middle lobe, bronchus or lung

C34.3

COPY

Malignant neoplasm of lower lobe, bronchus or lung

C34.30

COPY

Malignant neoplasm of lower lobe, unspecified bronchus or lung

C34.31

COPY

Malignant neoplasm of lower lobe, right bronchus or lung

C34.32

COPY

Malignant neoplasm of lower lobe, left bronchus or lung

C34.8

COPY

Malignant neoplasm of overlapping sites of bronchus and lung

C34.80

COPY

Malignant neoplasm of overlapping sites of unspecified bronchus and lung

C34.81

COPY

Malignant neoplasm of overlapping sites of right bronchus and lung

C34.82

COPY

Malignant neoplasm of overlapping sites of left bronchus and lung

C34.9

COPY

Malignant neoplasm of unspecified part of bronchus or lung

C34.90

COPY

Malignant neoplasm of unspecified part of bronchus or lung

C34.91

COPY

Malignant neoplasm of unspecified part of right bronchus or lung

C34.92

COPY

Malignant neoplasm of unspecified part of left bronchus or lung

Z51.12

COPY

Encounter for antineoplastic immunotherapy 

If infusion for antineoplastic immunotherapy is the only reason for the patient encounter, physicians and hospitals may report ICD-10-CM code “Z51.12 Encounter for antineoplastic immunotherapy” as the primary diagnosis.

OPDIVO may be purchased through the distributors listed below.

Physician Offices

Specialty Distributor Phone Orders Fax Orders and Website
Besse Medical 1-888-711-5469
Monday-Friday,
7 AM-11 PM ET
https://www.besse.com
Cardinal Health Specialty Pharmaceutical Distribution 1-877-453-3972
Monday-Friday,
7 AM-6 PM CT
(24-hour emergency on call)
https://specialtyonline.cardinalhealth.com
CuraScript Specialty Distribution 1-877-599-7748
Monday-Friday,
8 AM-7 PM ET
https://www.
curascriptsd.com
McKesson Specialty Health 1-800-482-6700
Monday-Friday,
7 AM-7 PM CT
https://mscs.
mckesson.com
Morris & Dickson Specialty 1-800-710-6100
Monday-Friday,
8 AM-6 PM CT
Fax: 1-318-524-3096
https://www.mdspecialtydist.com
Oncology Supply 1-800-633-7555
Monday-Friday,
8 AM-7 PM CT
https://www.oncologysupply.com

For offices that prefer to use the services of a specialty pharmacy, specialty pharmacies can obtain OPDIVO from the distributors listed above.

Hospitals and Infusion Centers

Specialty Distributor Phone Orders Fax Orders and Website
ASD Healthcare 1-800-746-6273 Monday-Thursday,
7 AM-6:30 PM CT; Friday,
7 AM-6 PM CT
Fax: 1-800-547-9413
https://www.asdhealthcare.com
Cardinal Health Specialty Pharmaceutical Distribution 1-866-677-4844 Monday-Friday,
7 AM-6 PM CT
(24-hour emergency on call)
Fax: 1-614-553-6301
https://orderexpress.cardinalhealth.com
DMS Pharmaceutical Group, Inc. 1-877-788-1100
Monday-Friday,
8:30 AM-5 PM CT
Fax: 1-847-518-1105
www.dmspharma.com
McKesson Plasma and Biologics 1-877-625-2566
Monday-Friday,
8 AM-6:30 PM CT
Fax: 1-888-752-7626
https://connect.mckesson.com
Morris & Dickson Specialty 1-800-710-6100 Fax: 1-318-524-3096
https://www.mdspecialtydist.com

Puerto Rico Hospitals and Clinics

Authorized Distributor Phone Orders Fax Orders and Website
AmerisourceBergen Puerto Rico 1-844-222-2273 https://abcorder.amerisourcebergen.com

Above information is accurate as of 11/21.

The OPDIVO distribution program includes extended payment terms to Bristol Myers Squibb authorized OPDIVO distributors. Healthcare providers and institutions should contact their OPDIVO distributor to understand specific payment terms that may be available to them from their distributor.

Please see U.S. Full Prescribing Information for OPDIVO.

FDA Approval Letters as Posted by the FDA:

OPDIVO for patients with metastatic non-squamous NSCLC who have progression on or after platinum-based chemotherapy* - Approved on 10/09/2015

View Letter

OPDIVO for patients with metastatic squamous NSCLC who have progression on or after platinum-based chemotherapy* - Approved on 03/04/2015

View Letter

Flat Dosing for OPDIVO (240 mg every 2 weeks) - Approved on 09/13/2016

View Letter

Flat Dosing for OPDIVO (480 mg every 4 weeks) - Approved on 03/05/2018

View Letter

Availability of OPDIVO 120 mg vial – Approved on 08/27/2021

View Letter

*Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Please see U.S. Full Prescribing Information for OPDIVO for complete indications.

Coding for OPDIVO is dependent on the insurer and the care setting in which the drug will be administered. Oncology practices need to make coding decisions based on the diagnosis and treatment of each patient and the specific insurer requirements.

Please see U.S. Full Prescribing Information for OPDIVO.

*Healthcare providers should code healthcare claims based upon the service that is rendered, the patient's medical record, the coding requirements of each health insurer, and best coding practices. Coding information provided under this heading does not provide a guarantee of reimbursement and should be considered together with all applicable coding guidance and standards. All of the coding information presented by this website is applicable to outpatient procedures only.

†CPT codes and descriptions only are ©2019 by American Medical Association (AMA). All rights reserved. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association.

References:

  1. American Medical Association. 2020 HCPCS Level II. Professional ed. Chicago, IL: American Medical Association; 2020.
  2. Centers for Medicare & Medicaid Services. MLN Matters, Number MM9603 Revised. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9603.pdf. Revised June 10, 2016. Accessed November 15, 2019.
  3. Palmetto GBA. Medicare Part A Billing Guide. May 2017. http://www.palmettogba.com/Palmetto/Providers.Nsf/files/ Part_A_Billing_Guide.pdf/$File/Part_A_Billing_Guide.pdf. Accessed October 10, 2019.
  4. American Medical Association. CPT Professional 2020. Professional ed. Chicago, IL: American Medical Association; 2019.
  5. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  6. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/Medicare/Coding/ICD10/2020-ICD-10-CM. Accessed September 1, 2021.

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Support Center icon
Support Center: 1-800-861-0048
am to 8 pm ET, Mon - Fri
Schedule a Call icon
Schedule a call from a Patient Access SpecialistSchedule a Call >
Request a Visit icon
Request a visit from a BMS Access & Reimbursement ManagerRequest a Visit >
Schedule a Call Request a Visit

BMS Logo

©2022 Bristol-Myers Squibb Company. All rights reserved. Access Support is a registered trademark of Bristol-Myers Squibb Company.

Use of the information on this site is subject to the terms of our Legal Notice and Privacy Statement. The coding, coverage, and payment information contained within this website is current as of 03/22.

1506-US-2101816 03/22